Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)

Cellular and Molecular Life Sciences

Volumn 57, Issue 10, 2000, Pages 1408-1422

  Sluis Cremer, N ^a   Arion, D ^a   Parniak, M A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antiviral drug resistance; Chain termination; DNA polymerization; Human immunodeficiency virus type 1; Nucleoside reverse transcriptase inhibitors; Phosphorolysis; Pyrophosphorolysis; Reverse transcriptase

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; DNA POLYMERASE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

DNA SYNTHESIS; ENZYME ACTIVITY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; POINT MUTATION; POLYMERIZATION; REVIEW; VIRUS INFECTION; VIRUS RESISTANCE;

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033770149     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000626     Document Type: Review

References (72)

1. Inhibitors of HIV-1 reverse transcriptase
2. Phosphorylation of 3'-azido-3'-dideoxythymidine and selective interaction of the 5'-triphosphates with human immunodeficiency virus reverse transcriptase
3. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo
4. Touching the heart of HIV-1 drug resistance: The fingers close down on the dNTP at the polymerase active site
5. Closing in on HIV drug resistance
6. Resistance to antiretroviral compounds: Implications for the clinical management of HIV infection
7. Human immunodeficiency virus reverse transcriptase
8. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
9. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer
10. Nucleoside drug resistance in HIV-1 reverse transcriptase
11. Mechanism and fidelity of HIV reverse transcriptase
12. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase
13. Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization
14. Refined model for primer/template binding by HIV-1 reverse transcriptase: Pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate
15. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors
16. The structure of the unliganded reverse transcriptase from the human immundodeficiency virus type 1
17. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: Implications of conformational changes for polymerization and inhibition mechanisms
18. Crystal structure of human immunodeficiency virus type I reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA
19. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution
20. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
21. Crystal structures of open and closed forms of binary and ternary complexes of the large fragment of Thermus aquaticus DNA polymerase I: Structural basis for nucleotide incorporation
22. DNA polymerases: Structural diversity and common mechanisms
23. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3TC
24. The K65R mutant reverse transcriptase associated with HIV-1 resistance to 2',3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine and 2',3-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro
25. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase
26. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]-adenine (PMEA)
27. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy
28. Mutational analysis of K65 of HIV-1 reverse transcriptase
29. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase
30. Crystal structures of the Klenow fragment of Thermus aquaticus DNA polymerase I complexed with deoxyribonucleoside triphosphates
31. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
32. Rapid changes in human immundodeficiency virus type 1 RNA load and appearance of dug-resistant virus populations in persons treated with lamivudine (3TC)
33. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase
34. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids
35. Sensitivity of wild-type human immunodeficiency virus type I reverse transcriptase to didoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not
36. Decreased processivity of human immunodeficiency virus type I containing didanosine-selected mutation Leu74Val: A comparative analysis of RT variants Leu74Val and Lamivudine-selected Met184Val
37. Characterization of reverse transcriptase activity and susceptibility to ther nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT multicentre study
38. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency strains resistant to 3'-azido-3'-deoxythymidine
39. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT)
40. Fifth mutation in human immunodeficiency virus type I reverse transcriptase contributes to the development of high-level resistance to zidovudine
41. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
42. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type I reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine
43. 3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes
44. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate
45. Pre-steady-state kinetic characterization of wild type and 3'-azido, 3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: Implications of RNA-directed DNA polymerization in the mechanism of AZT resistance
46. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
47. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide dependent mechanism
48. HIV resistance to zidovudine: The role of pyrophosphorolysis
49. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
50. Enhanced binding of azidothymidine-resistant human immunodeficiency virus type 1 reverse transcriptase to the 3'-azido-3'-dideoxythymidine 5'-monophosphate-terminated primer
51. Luminescent immobilized enzyme test systems for inorganic pyrophosphate: Assays using firefly luciferase and nicotinamide-mononucleotide adenylyl transferase or adenosine-5'-triphosphate sulfurylase
52. Studies on the mechanism of human immunodeficiency virus reverse transcriptase: Steady-state kinetics, processivity and polynucleotide inhibition
53. Catalytic properties of the reverse transcriptases of human immunodeficiency viruses types 1 and 2
54. Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine sensitivity to azidothymidine-resistant HIV-1 reverse transcriptase
55. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
56. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine
57. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
58. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
59. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
60. Potential mechanism for sustained antiviral efficacy of AZT-3TC combination therapy
61. Site-specific mutageneis of AIDS virus reverse transcriptase
62. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
63. Novel mutations in reverse transcriptase of human immunodeficiency virus type I reduce susceptibility to phosphonoformic acid in laboratory and clinical isolates
64. Characterization of phosphonoformic acid-resistant strains of human immunodeficiency virus type 1
65. Zidovudine resistance is supressed by mutations conferring resistance of human immunodeficiency virus type 1 to phosphonoformic acid
66. Coresistance to zidovudine and phosphonoformic acid is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase
67. The M184V mutation in the reverse transcriptase of the human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis
68. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
69. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates
70. Analysis of amino acid insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase
71. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
72. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in theyrapy-naive patients receiving stavudine plus didanosine combination therapy